PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

131 articles indexed across 16 specialties, each reviewed by a licensed pharmacist before publication.

⭐ Featured free samples

Three of our best full deep-analysis reports: hand-picked, free to read in full, no subscription required.

🔓 Free Sample
Nephrology / Renal Pharmacy ConfirmatoryGrade: Moderate

Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD

American journal of cardiovascular drugs : drugs, devices, and other interventions · Jul 20, 2026

Finerenone emerges as the safer choice for CKD patients.

Read Free →
🔓 Free Sample
Neurology / Neuropharmacology ConfirmatoryGrade: Low

Tenecteplase Shortens Stroke Treatment and Transfer Times

JAMA network open · Jul 13, 2026

Tenecteplase speeds up stroke thrombolysis compared to alteplase.

Read Free →
🔓 Free Sample
Rheumatology / Immunology ConfirmatoryGrade: Moderate

EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations

Annals of the rheumatic diseases · Jun 13, 2026

New EULAR guidelines redefine RA management with DMARDs.

Read Free →
Showing 1 from 1 topic.Sort: Newest | Oldest
2026 AHA/ASA Acute Ischemic Stroke Guideline: Major Shifts in Thrombolysis, EVT, and Systems
🔓 Free Teaser Ischemic Stroke Practice-changing Grade: High
Prabhakaran S, Gonzalez NR, Zachrison KS, et al.
📅 Jan 26, 2026 · Stroke

The 2026 AHA/ASA guideline replaces the 2018 guideline and its 2019 update, elevating tenecteplase to a co-first-line thrombolytic with alteplase, endorsing imaging-selected thrombolysis out to 9 hours and in wake-up stroke, expanding endovascular thrombectomy to large ischemic cores and basilar occlusion, and reversing intensive glucose and blood-pressure targets.